The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen Inc. (NASDAQ: AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA ...

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

BioNTech is set to receive up to $7.6 billion in future payments based on certain milestones. (Yahoo! Finance) Amgen’s drug Imdelltra cut small cancer lung cell death risk by 40%. The drug has ...

Amgen's positive lung cancer data: The company's drug, Imdelltra, reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an ...